India's GM clamor mounts

  title={India's GM clamor mounts},
  author={K. Jayaraman},
  journal={Nature Biotechnology},
volume 30 number 4 APrIl 2012 nature biotechnology “It’s pioneering technology based on a simple, elegant concept,” enthuses Amgen’s Chang. “You can view it as turbocharging immunotherapy.” Other tumor-associated antigens that Micromet has targeted with BiTE antibodies include carcinoembyronic antigen and prostatespecific membrane antigen. Blinatumomab is also undergoing trials in non-Hodgkin’s lymphoma and could have use in other B-cell cancers, as CD19 is present throughout B-cell development… CONTINUE READING